STATEMENTS OF STOCKHOLDERS' (DEFICIT) - USD ($)	Common Stock	Additional Paid-in Capital	Retained Deficit	Total
Balance at Feb. 28, 2023	$ 131,449	$ 126,609,599	$ (126,754,775)	$ (13,727)
Balance (in shares) at Feb. 28, 2023	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D.		64,517		64,517
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.		166,097		166,097
Net loss			(287,405)	(287,405)
Balance at May. 31, 2023	$ 131,449	126,840,213	(127,042,180)	(70,518)
Balance (in shares) at May. 31, 2023	131,448,444
Balance at Feb. 29, 2024	$ 131,449	127,933,634	(128,090,206)	(25,123)
Balance (in shares) at Feb. 29, 2024	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D.		58,517		58,517
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.		210,070		210,070
Net loss			(371,332)	(371,332)
Balance at May. 31, 2024	$ 131,449	$ 128,202,221	$ (128,461,538)	$ (127,868)
Balance (in shares) at May. 31, 2024	131,448,444